A registrational study of Briquilimab in Chronic-inducible-urticaria
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs Briquilimab (Primary)
- Indications Chronic urticaria
- Focus Registrational; Therapeutic Use
- 26 Nov 2024 New trial record
- 23 Oct 2024 According to a Jasper Therapeutics media release, company planned to commence in the second half of 2025.